Results of micropulse cyclophotocoagulation in patients with early stages of primary open-angle glaucoma
https://doi.org/10.53432/2078-4104-2022-21-4-22-28
Abstract
PURPOSE. To evaluate the capabilities of micropulse transscleral cyclophotocoagulation (MP-TSCPC) in patients with early stages of glaucoma.
METHODS. The study included 38 patients with early stages of primary open-angle glaucoma who underwent MP-TSCPC with SUPRA 810 (“Quantel Medical”, France) as primary surgical treatment. The follow-up period averaged 17±11 months (from 6 to 30 months). The Kaplan-Meier scale was used to assess the cumulative success of laser treatment.
RESULTS. The postoperative period was uneventful. One month after MP-TSCPC a significant hypotensive effect was observed, averaging 41.5% from the baseline. After 6 months, the hypotensive effect continued to persist and averaged 36.1%. By 12 months, the hypotensive effect remained stable, IOP averaged 16.0±3.5 mm Hg, which was 31% from the baseline. No changes in best corrected visual acuity (BCVA) were detected during the observation period. Target intraocular pressure (IOP) was achieved in all cases. Optical coherence tomography and perimetry findings remained stable or improved.
CONCLUSION. MP-TSCPC in patients with early stages of glaucoma leads to a pronounced stable hypotensive effect during the follow-up period, averaging 31% (from 20% to 50%). An improvement in the quality of life was noted due to the cease or reduction in the number of instillations. Monitoring of patients continues in order to develop practical recommendations for the indications and regimens of MP-TSCPC in the early stages of glaucoma.
About the Authors
I. E. Ioshin
Clinical Hospital of the Presidential Administration
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Head of the Center of Ophthalmology.
45 Losinoostrovskaya St., Moscow, 107143
A. I. Tolchinskaya
Clinical Hospital of the Presidential Administration
Russian Federation
Russian Federation
Dr. Sci. (Med.), Ophthalmologist.
45 Losinoostrovskaya St., Moscow, 107143
A. V. Rakova
Clinical Hospital of the Presidential Administration
Russian Federation
Russian Federation
Cand. Sci. (Med.), Ophthalmologist.
45 Losinoostrovskaya St., Moscow, 107143
I. V. Maksimov
Clinical Hospital of the Presidential Administration
Russian Federation
Russian Federation
Ophthalmologist.
45 Losinoostrovskaya St., Moscow, 107143
References
1. Alekseev V.N., Egorov E.A., Malevannaya O.A. Analysis of the main causes of the progression of primary open-angle glaucoma. RMJ Clinical ophthalmology 2014; 4:218-223.
2. Glaucoma. National guidance. Edited by Egorov E.A., Erichev V.P. Moscow, GEOTAR-Media Publ., 2013. 824 p.
3. Boland M.V., Chang D.S., Frazier T., Plyler R., Friedman D.S. Electronic monitoring to assess adherence with once-daily glaucomamedications and risk factors for nonadherence: the automated dosing reminder study. JAMA Ophthalmol 2014; 132(7):838-844. https://doi.org/10.1001/jamaophthalmol.2014.856
4. Dietlein T.S., Rosentreter A., Lappas A. Complexities of medical glaucoma therapy — the elderly patient in focus. Klin Monbl Augenheilkd 2016; 233(2):138-142 https://doi.org/10.1055/s-0041-110447
5. Friedman D.S., Quigley H.A., Gelb L., Tan J., Margolis J., Shah S.N. et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci 2007; 48(11):5052-5057. https://doi.org/10.1167/iovs.07-0290
6. Dolgova I.G., Malishevskaya T.N., Lazareva A.S. Compliance and the patient's school: solving a common problem. Glaukoma 2009; 3:35-41.
7. Egorov E.A., Lovpache J.N., Kharkovskiy A.O. Compliance — what is behind this term? RMJ Clinical ophthalmology 2008; 3:84-86.
8. Casanova S.Yu. Analysis of adherence to treatment of patients with chronic diseases. Natsional’nyi zhurnal glaukoma 2018; 17(3):97-110.
9. Kuroyedov A.V. Compliance in the therapy of a glaucoma patient. Moscow: GEOTAR-Media; 2017.
10. Vaughan D., Asbury T., Riordan–Eva P., «General Ophthalmology», 15th Edition, Appleton & Lange, Stamford, Connecticut, 1999.
11. Wise JB, Witter SL. Argon laser therapy for open–angle glaucoma: a pilot study. Archive of Ophthalmology and Glaucoma 1979; 97:319-322.
12. Nguyen A.T., Maslin J.S., Noecker J.R. Early results of micropulse trans-scleral cyclophotocoagulation for the treatment of glaucoma. Eur J Ophtalmol 2019; 303. https://doi.org/10.1177/1120672119839303
13. Varikuti V.N.V, Shan P., Rai O., Chaves A.C., Miranda A., Lim B. et al. Outcomes of micropulse transscleral cyclophotocoagulation in eyes with good central vision. J Glaucoma 2019; 28:901-905. https://doi.org/10.1097/IJG.0000000000001339
14. Lovpache. J.N., Zavadsky P. Ch., Zvereva O.G., Kuroyedov A.V. Compliance and persistence in patients with primary open-angle glaucoma from the point of view of an ophthalmologist. Natsional’nyi zhurnal glaukoma 2020; 19:11-21.
15. Quigley H.A., Jampel H.D. How are glaucoma patients identified? J Glaucoma 2003; 12(6):451-455. https://doi.org/10.1097/00061198-200312000-00001.
16. Sanchez F.G., Lerner F., Sampaolesi J., Noecker R. et al. Efficacy and Safety of Micropulse(R) Transscleral Cyclophotocoagulation in Glaucoma. Arch Soc Esp Oftalmol 2018; 93(12):573-579. https://doi.org/10.1016/j.oftal.2018.08.003
17. Aquino MC, Barton K, Tan AMW, Sng C, Li X, Loon SC, Chew PT. Micropulse versus continuous wave transscleral diode cyclophotocoagulation in refractory glaucoma. Clinical and Experimental Ophthalmology 2015; 43(1):40-46. https://doi.org/10.1111/ceo.12360
18. Grippo M.T., Sanchez G.F., Stauffer J., Marcellino G. Micro-Pulse® Transscleral Laser Therapy – Fluence May Explain Variability in Clinical Outcomes: A Literature Review and Analysis. Clinical ophthalmology (Auckland, N.Z.) 2021; 15:2411-2419. https://doi.org/OPTH.S313875
19. Latina M., Lachkar Y. Ranking Laser in Glaucoma Treatment. Insert to glaucoma today 2021; 121(1):28-31.
20. Ioshin I.,E., Tolchinskaya A.I. Maksimov I.V Rakova A.V. Experience of repeated micropulse cyclophotocoagulation in the treatment of patients with refractory glaucoma of various stages. Natsional’nyi zhurnal glaucoma 2021; 20(3):30-39. https://doi.org/10.25700/2078-4104-2021-20-3-30-39
21. Sarrafpour S., Saleh D., Ayoub S., Radcliffe N.M. Micropulse transscleral cyclophotocoagulation: A look at long-term effectiveness and outcomes. Ophthalmology Glaucoma 2019; 2(3):167-71. https://doi.org/10.1016/j.ogla.2019.02.002
22. Al Habash A, AlAhmadi AS. Outcome of MicroPulse® transscleral photocoagulation in different types of glaucoma. Clin Ophthalmol 2019; 13:2353-2360. https://doi.org/10.2147/OPTH.S226554
23. Magacho L, Lima FE, Avila MP. Double-session micropulse transscleral laser (cyclo G6) as a primary surgical procedure for glaucoma. J Glaucoma 2020; 29(3):205-210. https://doi.org/10.1097/IJG.0000000000001426
Review
For citations:
Ioshin I.E., Tolchinskaya A.I., Rakova A.V., Maksimov I.V. Results of micropulse cyclophotocoagulation in patients with early stages of primary open-angle glaucoma. National Journal glaucoma. 2022;21(4):22-28. (In Russ.) https://doi.org/10.53432/2078-4104-2022-21-4-22-28
Views:
419
Email this article 